Canagliflozin

證據等級: L5

預測適應症: 0 個

Canagliflozin: Drug Repurposing Evaluation — No TxGNN Prediction Data Available

One-Sentence Summary

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor widely used internationally for Type 2 diabetes, heart failure, and chronic kidney disease. However, this Evidence Pack contains no TxGNN predicted indications, and the drug has no Taiwan regulatory approvals on record. A complete repurposing evaluation cannot be generated until prediction data and mechanism of action information are retrieved.

Quick Overview

Item	Content
Original Indication	No Taiwan approval on record
Predicted New Indication	No prediction data available
TxGNN Prediction Score	N/A
Evidence Level	Below L5 — no predictions, no supporting studies retrieved
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why This Evaluation Cannot Proceed

This Evidence Pack is missing two foundational data elements required for a repurposing evaluation:

No TxGNN predictions — The predicted_indications array is empty. Without a model prediction, there is no candidate indication to evaluate, and no direction for evidence search.
MOA data absent — The mechanism of action field was not successfully retrieved from DrugBank despite the query returning a result. Without MOA, the biological plausibility of any repurposing hypothesis cannot be assessed.

Canagliflozin is a well-characterised drug internationally (SGLT2 inhibition, renal glucose excretion, haemodynamic and cardioprotective effects), but these facts cannot substitute for the structured pipeline output required to proceed with this workflow.

Clinical Trial Evidence

Currently no related clinical trials are listed in this Evidence Pack.

Literature Evidence

Currently no related literature is listed in this Evidence Pack.

Taiwan Market Information

Canagliflozin has no registered drug authorizations in Taiwan as of this Evidence Pack's data cutoff (2026-04-20).

Safety Considerations

Please refer to the package insert for safety information.

No warnings, contraindications, or drug interaction data are present in this Evidence Pack. All safety fields returned no data or were not queryable.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack lacks TxGNN prediction output and MOA data — the two inputs that drive every downstream section of a repurposing report. Proceeding without them would require fabricating analytical content, which is not acceptable.

To proceed, the following is needed:

Re-run TxGNN pipeline — Confirm whether Canagliflozin was processed through the model; retrieve predicted_indications with scores, clinical trial links, and literature PMIDs
Retrieve MOA from DrugBank — DrugBank query returned a result (query log entry #3) but MOA was not extracted; re-parse the DrugBank record for mechanism, pharmacodynamics, and categories
Download Taiwan package insert — TFDA query returned a result (query log entry #4); extract warnings, contraindications, and approved indications from the PDF
Re-run DDI query — Drug interaction query returned not_found; verify if this reflects true absence or a query parameter issue
Clarify market scope — If the target market is Germany (BfArM) rather than Taiwan (TFDA), switch the regulatory query source accordingly; Canagliflozin (Invokana®) is authorised in the EU
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.